Biochemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
Biochemotherapy leads to lower progression‐free survival† compared with chemotherapy (high certainty).
Biochemotherapy leads to higher tumour response compared with chemotherapy (high certainty).
Biochemotherapy leads to higher toxicity (≥ G3) compared with chemotherapy (high certainty).
High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
High‐dose chemotherapy showed no clear difference in event‐free survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
High‐dose chemotherapy leads to higher treatment‐related mortality compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
High‐dose chemotherapy showed no clear difference in second cancers at 4 ‐ 9‐year median compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
Polychemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
Polychemotherapy showed no clear difference in progression‐freesurvival† compared with chemotherapy (high certainty).
Polychemotherapy probably leads to higher tumour response compared with chemotherapy (moderate certainty).
Polychemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
It is very uncertain whether combination chemotherapy changes overall survival (3 years) compared with single‐agent chemotherapy (very low certainty).
It is very uncertain whether combination chemotherapy changes disease‐free survival (3 years) compared with single‐agent chemotherapy (very low certainty).
Combination chemotherapy leads to higher complete response rate after preoperative chemoradiation (ypCR) compared with single‐agent chemotherapy (high certainty).
Combination chemotherapy probably leads to higher toxicity ‐ early adverse events G3/4 compared with single‐agent chemotherapy (moderate certainty).
Combination chemotherapy showed no clear difference in metastases intra‐abdominal compared with single‐agent chemotherapy (moderate certainty).
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with maintenance radiotherapy (low certainty).
Maintenance chemotherapy showed no clear difference in 3‐year OS compared with maintenance radiotherapy (low certainty).
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with maintenance radiotherapy (low certainty).